Document › Details
Sequenom, Inc.. (9/9/09). "Press Release: Sequenom Announces Partnership with Geneworks for Sales and Marketing of MassARRAY Systems and Applications in Australia". San Diego, CA.
|Organisation||Sequenom Inc. (Nasdaq: SQNM)|
|Organisation 2||GeneWorks Technologies Pty Ltd.|
|Product 2||molecular diagnostics|
|Person||Monko, Michael (Sequenom 200608– Senior VP Sales + Marketing before UpState Chemicon before Invitrogen Corp)|
|Person 2||Guilhaus, Peter (GeneWorks 200901 CEO)|
SEQUENOM, Inc. (NASDAQ: SQNM) and GeneWorks Pty. Ltd. today announced an exclusive sales agency agreement under which GeneWorks will assist SEQUENOM in expanding its sales & marketing presence in Australia. The partnership will initially focus on new business development activity across Australia. GeneWorks has significant experience and a strong reputation in the supply of genomics technologies and reagents and is an Australian manufacturer of high quality oligonucleotides and offers a range of genetic analysis services including Next Generation Sequencing services.
"Given our introduction of the new MassARRAY Compact 96 system, OncoCarta oncogene mutation profiling panel, and our expansion into translational and clinical research sectors, we are excited about the capabilities that GeneWorks brings to assist us in expanding our customer base in Australia" said Mike Monko, senior vice president of sales & marketing at SEQUENOM. "Australia remains a key market for us in the Asia Pacific region and with our ongoing direct presence in Australia through our Asia Pacific office based in Queensland, we expect to see substantial business growth in this region over the coming years."
Peter Guilhaus, managing director of GeneWorks added, "we're excited and pleased to be partnering with SEQUENOM in Australia. SEQUENOM's MassARRAY system and related kits complement our product and services portfolio nicely. We're looking forward to supporting this powerful technology, and in conjunction with our oligo and genome analysis services, providing our customers with a comprehensive solution to their research needs."
SEQUENOM, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. SEQUENOM develops innovative technology, products and diagnostic tests that target and serve discovery & clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. SEQUENOM maintains a Web site at http://www.sequenom.com to which SEQUENOM regularly posts copies of its press releases as well as additional information about SEQUENOM. Interested persons can subscribe on the SEQUENOM Web site to email alerts or RSS feeds that are sent automatically when SEQUENOM issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site. SEQUENOM®, OncoCartaTM and MassARRAY® are trademarks of SEQUENOM, Inc. All other trademarks and service marks are the property of their respective owners.
GeneWorks Pty. Ltd. established in 1996 is a major Australian supplier of leading edge molecular biology research products. Centrally headquartered in Adelaide, South Australia with sales offices in all Australian capital cities as well as Auckland NZ, it services and supplies the Australian and New Zealand markets with a select range of innovative leading edge equipment, reagents, consumables and associated services. Our core business is the synthesis and supply of custom oligonucleotides and next generation Genome Analysis Services. GeneWorks has implemented and maintains a quality management system and is ISO 9001:2008 certified. Our highly qualified staff are motivated to provide the highest possible level of professionalism and support of our products and services, allowing researchers to achieve their goals with maximum efficiency, reliability and confidentiality.
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the Company expanding its sales and marketing presence and customer base in Australia, the Company's expectation of substantial business growth in Australia over the coming years, the performance of the MassARRAY Compact 96 system, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with market demand for and acceptance and use by customers of new products such as the MassARRAY Compact 96 system, the Company's ability to develop and commercialize new technologies and products, particularly new technologies such as genetic analysis platforms, noninvasive prenatal and other diagnostic tests and laboratory developed tests, reliance upon the collaborative efforts of other parties, the Company's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, government regulation particularly with respect to diagnostic products and laboratory developed tests, obtaining or maintaining regulatory approvals, the independent investigation and other risks detailed from time to time in the Company's Annual Report on Form 10-K for the year ended December 31, 2008 and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.
Company Contact Ian Clements, PhD Sr. Director, Corp. Communications +1 (858) 202-9000 Investor Relations Contact Lippert/Heilshorn & Associates Jody Cain (firstname.lastname@example.org) +1 (310) 691-7100
Media Relations Pure Communications Sheryl Seapy +1 (949) 608-0841
Record changed: 2016-03-19
More documents for Sequenom (Group)
-  Laboratory Corporation of America Holdings (LabCorp). (7/27/16). "Press Release: LabCorp Announces Agreement to Acquire Sequenom". Burlington, NC & San Diego, CA....
-  Agena Bioscience, Inc.. (2/24/15). "Press Release: Agena Bioscience Launches MassARRAY 24-Well System for Affordable Genetic Testing, Liquid Biopsies". San Diego, CA....
-  Sequenom, Inc.. (6/16/14). "Press Release: Sequenom, Inc. Receives U.S. FDA Premarket Clearance". San Diego, CA....
-  Sequenom, Inc.. (5/30/14). "Press Release: Sequenom, Inc. Reports Sales of Bioscience Business". San Diego, CA....
-  Atlas Biolabs GmbH. (7/23/10). "Press Release: Atlas Biolabs Expands Services in Molecular Genetics to High-throughput SNP-genotyping Based on Mass Spectrometry". Berlin....
-  Sequenom, Inc.. (5/12/10). "Press Release: Sequenom Announces $51.6 Million Private Placement". San Diego, CA....
-  Sequenom, Inc.. (4/19/10). "Press Release: Sequenom Introduces the MassARRAY Analyzer 4 System. Next-generation Proprietary Platform Makes High-performance Mass Spectrometry Available to Broad Market". San Diego, CA....
-  Sequenom, Inc.. (3/15/10). "Press Release: Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results. Full Year 2009 Revenues of $37.9 Million with Year End Cash and Equivalents of $42.7 Million". San Diego, CA....
-  Sequenom, Inc.. (2/16/10). "Press Release: Sequenom Announces Launch of SensiGene Fetal(XY) (Fetal Sex Determination)". San Diego, CA....
-  Sequenom, Inc.. (2/9/10). "Press Release: Sequenom Licenses Worldwide Rights to Develop Age-related Molecular Degeneration Diagnostic Test". San Diego, CA....
To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to email@example.com and simply fill the subject line with the word »MSC newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]